Roche said the newly developed analyzers will be marketed under Roche’s cobas brand and will include three platforms which will address a range of customer needs, from low-volume testing to the high-throughput demands of commercial laboratories, along with a complete menu of coagulation assays.
Roche Diagnostics and Diagnostica Stago will receive separate paths in laboratory coagulation in territories where Roche distributes the Stago line of lab coagulation analyzers.